Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer

about

Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer

Item

http://www.wikidata.org/entity/Q39270453

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Harnessing antitumor immunity: ...... nflammatory response to cancer

@en

Harnessing antitumor immunity: ...... flammatory response to cancer.

@nl

type

Item

label

Harnessing antitumor immunity: ...... nflammatory response to cancer

@en

Harnessing antitumor immunity: ...... flammatory response to cancer.

@nl

prefLabel

Harnessing antitumor immunity: ...... nflammatory response to cancer

@en

Harnessing antitumor immunity: ...... flammatory response to cancer.

@nl

P1476

Harnessing antitumor immunity: ...... nflammatory response to cancer

@en

P2093

Kimberly A Silverio

http://www.w3.org/2001/XMLSchema#string

Shyam A Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting

Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy

CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages

Nivolumab plus ipilimumab in advanced melanoma.

The distribution of secondary growths in cancer of the breast. 1889

Nivolumab in previously untreated melanoma without BRAF mutation

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1

IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells.

Up-regulation of Th17 cells may underlie inhibition of Treg development caused by immunization with activated syngeneic T cells.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

P304

2015-2020

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2017.5721

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28454356

http://www.w3.org/2001/XMLSchema#string

P932

5403274

http://www.w3.org/2001/XMLSchema#string